Nimodipine Dosing and Administration for Subarachnoid Hemorrhage
Administer nimodipine 60 mg orally every 4 hours for 21 consecutive days, starting as soon as possible within 96 hours of SAH onset. 1, 2
Standard Dosing Protocol
The FDA-approved and guideline-recommended regimen is:
- Dose: 60 mg (two 30 mg capsules) every 4 hours
- Duration: 21 consecutive days
- Timing: Initiate within 96 hours of SAH onset 2
- Route: Enteral administration only—NEVER administer intravenously 2
This dosing is supported by the 2023 AHA/ASA guidelines, which emphasize that continued enteral administration at 60 mg every 4 hours is beneficial for preventing delayed cerebral ischemia (DCI) and improving functional outcomes 1.
Administration Methods
For Conscious Patients Who Can Swallow
- Swallow capsules whole with liquid
- Administer at least 1 hour before or 2 hours after meals (fasting state improves bioavailability) 2, 3
- Avoid grapefruit juice 2
For Unconscious Patients or Those Unable to Swallow
- Pierce both ends of capsule with 18-gauge needle
- Extract contents with parenteral syringe
- Transfer to oral/enteral syringe labeled "Not for IV Use"
- Administer via nasogastric tube or PEG tube
- Flush with 30 mL normal saline 2
Critical safety note: Recent evidence shows nasogastric administration in fed states significantly reduces bioavailability 3. Maintain fasting conditions when possible.
Managing Hypotension
Hypotension is the most common reason for dose modification, occurring in 28-40% of patients 4, 5. The guidelines explicitly state that consistent administration should be maintained even with nimodipine-induced hypotension, which can be managed with standard medical interventions 1.
Dose Reduction Strategy
If hypotension occurs despite vasopressor support:
- Reduce to 30 mg every 4 hours 2
- Monitor blood pressure and heart rate closely
- Consider temporary stoppage only if significant BP variability occurs 1
Important caveat: Dose reduction is associated with worse outcomes. Only 43.6% of patients receive the full dose in clinical practice, and full dosing decreases the risk of unfavorable outcome (OR 0.895, p=0.029) 5. Maintain full dosing whenever hemodynamically feasible.
Alternative Dosing (30 mg every 2 hours)
Modified dosing of 30 mg every 2 hours has been studied as an alternative when standard dosing causes hypotension. This approach appears well-tolerated and may not be associated with worse functional outcomes 6, though it remains off-label and should be reserved for patients who cannot tolerate standard dosing.
Special Populations
Hepatic Impairment
Patients with liver cirrhosis have significantly increased bioavailability (approximately double Cmax):
- Reduce to 30 mg every 4 hours
- Monitor blood pressure and heart rate closely
- Consider discontinuation if adverse effects persist 2
Drug Interactions
- Strong CYP3A4 inhibitors: Contraindicated 2
- Strong CYP3A4 inducers: Generally avoid; may require dose increase if used 2
- Moderate/weak CYP3A4 inhibitors: May require dose reduction for hypotension 2
Duration Considerations
The full 21-day course is critical for efficacy. Recent propensity-matched data from 2026 shows that nimodipine administered for ≥14 days reduces vasospasm, delayed infarction, and improves functional outcomes, while shorter courses (<14 days) only reduce angiographic vasospasm without functional benefit 7.
Early Discharge
For highly selected good-grade SAH patients (WFNS I-III), abbreviated courses (<14 days) with early discharge may be safe, but this applies only to exceptional cases without radiographic or clinical vasospasm 8. For standard practice, complete the full 21-day course.
Key Evidence Points
The recommendation is based on:
- Original 1983 clinical trial data
- Meta-analysis of 16 trials involving 3,361 patients 1
- Consistent administration correlates inversely with DCI (ρ=-0.273, p<0.001) 1
- Disruption of nimodipine increases DCI incidence (ρ=0.431, p<0.001) 1
Critical pitfall: In real-world practice, only 33% of patients complete the full 21-day course 4. The most common reasons are premature discharge without home prescriptions (47%) and hypotension requiring dose reduction (39%) 4. Ensure nimodipine is prescribed at discharge if the patient leaves before day 21.